Technical Analysis for STX - Shield Therapeutics Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Historical STX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Shooting Star Candlestick | Bearish | 1.92% | |
| Lizard Bearish | Bearish Day Trade Setup | 1.92% | |
| Pocket Pivot | Bullish Swing Setup | 1.92% | |
| Doji - Bearish? | Reversal | 1.92% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Fell Below Upper Bollinger Band | 2 days ago |
| Rose Above Previous Day's High | 2 days ago |
| Up 5% | 2 days ago |
| Up 3% | 2 days ago |
| Up 2% | 2 days ago |
Get a Trading Sidekick!
Shield Therapeutics Plc Description
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company's product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. It also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Health Iron Pharmaceutical Medicine Pipe Clinic Pharmaceuticals Hospital Disease Clinical Trial Blood Pharmaceutical Industry Rtt Phosphate Clinical Research Kidney Disease Chronic Kidney Disease Design Of Experiments Anemia Inflammatory Bowel Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 153.0 |
| 52 Week Low | 31.75 |
| Average Volume | 1,609,485 |
| 200-Day Moving Average | 84.23 |
| 50-Day Moving Average | 42.14 |
| 20-Day Moving Average | 47.04 |
| 10-Day Moving Average | 49.12 |
| Average True Range | 3.45 |
| ADX | 33.02 |
| +DI | 34.14 |
| -DI | 10.18 |
| Chandelier Exit (Long, 3 ATRs ) | 47.04 |
| Chandelier Exit (Short, 3 ATRs ) | 52.86 |
| Upper Bollinger Band | 52.48 |
| Lower Bollinger Band | 41.59 |
| Percent B (%b) | 1.05 |
| BandWidth | 23.15 |
| MACD Line | 2.23 |
| MACD Signal Line | 1.67 |
| MACD Histogram | 0.5563 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 56.00 | ||||
| Resistance 3 (R3) | 56.00 | 55.00 | 55.50 | ||
| Resistance 2 (R2) | 55.00 | 54.24 | 55.00 | 55.33 | |
| Resistance 1 (R1) | 54.00 | 53.76 | 54.50 | 54.00 | 55.17 |
| Pivot Point | 53.00 | 53.00 | 53.25 | 53.00 | 53.00 |
| Support 1 (S1) | 52.00 | 52.24 | 52.50 | 52.00 | 50.83 |
| Support 2 (S2) | 51.00 | 51.76 | 51.00 | 50.67 | |
| Support 3 (S3) | 50.00 | 51.00 | 50.50 | ||
| Support 4 (S4) | 50.00 |
